Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 16/20 | 1.00 |
| ▸ | CCR1 | P32246 | 1/20 | 0.64 |
| ▸ | CCR5 | P51681 | 1/20 | 0.64 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13605161 | 1.00 | CCR2 (1.00) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL196068 | 0.95 | CCR2 (0.91) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL195030 | 0.95 | CCR2 (0.91) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL12233199 | 0.95 | CCR2 (0.91) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL1990719 | 0.88 | CCR2 (0.79) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL12206759 | 0.88 | CCR2 (0.79) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL12207219 | 0.88 | CCR2 (0.79) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL13713487 | 0.85 | CCR2 (0.80) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL3954242 | 0.81 | CCR2 (0.69) | CCR2RAB9ANPC1 | |
| SCHEMBL8317734 | 0.81 | CCR2 (0.69) | CCR2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2572716-A1 | Anti-inflammatory Composition | Cambridge Enterprise Limited (GB) | 2013-03-27 | — | — | EP | disclosed |
| US-7897620-B2 | Methods of using anti-inflammatory compounds | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| US-20100324089-A1 | Anti-inflammatory composition | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-20100113518-A1 | METHODS OF USING ANTI-INFLAMMATORY COMPOUNDS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
| US-7662967-B2 | Anti-inflammatory compounds and compositions | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-02-16 | — | — | US | disclosed |
| US-20090036486-A1 | 3-(2',2'-Dimethylpropanoylamino)tetrahydropyridin-2-one for prevention or treatment of inflammatory disorders, autoimmune diseases | CAMBRIDGE ENTERPRISE LIMITED THE OLD SCHOOLS (GB) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324089-A1 | Anti-inflammatory composition | TNF, IL1B, IL1A | CCR2 85/4885CCR1 169/4885CCR5 284/4885 |
| US-20090036486-A1 | 3-(2',2'-Dimethylpropanoylamino)tetrahydropyridin-2-one for prevention or treatment of inflammatory disorders, autoimmune diseases | TNF, NFKBIA, TPMT | CCR2 207/4885CCR1 214/4885CCR5 706/4885 |
| US-20100113518-A1 | METHODS OF USING ANTI-INFLAMMATORY COMPOUNDS | TNF, PTGES2, MMP8 | CCR2 133/4885CCR1 243/4885CCR5 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.